Oropharynx HPV-Mediated (p16+) (excluding Malignant Melanoma)

Primary Site Histology Schema Discriminator 1 Schema Discriminator 2
C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 8000-8700, 9700-9701 2
C111 8000-8700, 9700-9701 2 2

Notes

C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700, 9700-9701) C111 and Schema Discriminator 1: Nasopharynx/PharyngealTonsil: 2 AND Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700, 9700-9701) C019 Base of tongue, NOS C024 Lingual tonsil C051 Soft palate, NOS C052 Uvula C090 Tonsillar fossa C091 Tonsillar pillar C098 Overlapping lesion of tonsil C099 Tonsil, NOS C100 Vallecula C102 Lateral wall of oropharynx C103 Posterior wall of oropharynx C104 Branchial cleft (site of neoplasm) C108 Overlapping lesion of oropharynx C109 Oropharynx, NOS C111 Pharyngeal tonsil **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 10 *HPV-Mediated (p16+) Oropharyngeal Cancer*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** See the following schemas for the listed histologies * C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 1, 9 (8000-8700, 9700-9701): *Oropharynx (p16-)* * C111 and Schema Discriminator 1: Nasopharynx/PharyngealTonsil:1 (8000-8700, 9700-9701): *Nasopharynx* * 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9137, 9141-9230, 9240-9580, 9582: *Soft Tissue Head and Neck* * 8720-8790: *Melanoma Head and Neck* * 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9120, 9231, 9581: *Soft Tissue Other* * 8935-8936: *GIST* * 9140: *Kaposi Sarcoma* **Note 3:** p16 immunotesting is mandatory to use this staging system for HPV-associated cancer. HPV by in situ hybridization (ISH) may be done as an alternative. If a case of oropharyngeal cancer has p16+, then this chapter is used. If a case does not have p16 or HPV by ISH, then the case is staged by the p16- system.

Initial Context

Staging Methods

Expand All | Collapse All

Summary Stage 2018

Start

Additional Context
eod_2018_t = 90
eod_2018_m = 90
eod_2018_n = 90

Next Step

  2. EOD Primary Tumor
  3. ss2018_t

Next Step

  2. EOD Regional Nodes
  3. ss2018_n

Next Step

  2. EOD Mets
  3. ss2018_m

Next Step

  2. Summary Stage
  3. ss2018_derived

End

Outputs

Name Default Value Description NAACCR Item Metadata
Schema ID 00100 NAACCR #3800
None 		None
Derived Version {{ctx_alg_version}} None None
Derived Summary Stage 2018 9 NAACCR #762
None 		None